Attached files
file | filename |
---|---|
8-K - FORM 8-K - ERESEARCHTECHNOLOGY INC /DE/ | c10034e8vk.htm |
Exhibit 99.1
Media Contacts: Fiona Robinson The Scott Partnership Tel: +44 1477 539539 ert@scottpr.com |
News Release John Blakeley ERT +1 215 972 0420 jblakeley@ert.com |
ERT Announces the Appointment of Joel Morganroth, MD
as Interim CEO
as Interim CEO
PHILADELPHIA, PA, 21 December 2010/PRNewswire-FirstCall/ ERT (Nasdaq: ERES - News), a global
provider of technology and services to the pharmaceutical, biotechnology and medical device
industries, today confirmed that the effective date of the previously announced retirement of Dr.
Michael J. McKelvey, its President and CEO, is December 21, 2010.
Dr. Joel Morganroth, currently ERTs Chairman and Chief Scientific Officer, has also been elected
by the Board as President and CEO until ERT hires a permanent CEO. Dr. Morganroth has served as
the Chairman of ERTs Board of Directors since 1999 and as Chief Scientific Officer since April
2006. He previously served as the companys Chief Executive Officer from 1993 to March 2001 and
also has consulted for ERT since 1977. Dr. Morganroth is also a globally recognized cardiologist
and clinical researcher and has had more than 10 years experience as a medical review
officer/expert for the U.S. Food and Drug Administration (FDA).
Dr. Morganroth commented,
We thank Dr. McKelvey for his years of service and wish him well in his future endeavors.
ERT is a leading provider of innovative solutions and is well positioned for continued
growth. In my expanded role, I will continue to leverage my experience and knowledge of the
organization and domain expertise to strengthen our position in clinical research associated with
Cardiac Safety, Respiratory and electronic Patient Reported Outcomes [ePRO]. With our superb
management team, we will continue our goal of enhanced growth through the exciting development of
adjacent markets.
For further information on ERT and its technology and services please email info@ert.com, call +1
215 972 0420 or visit www.ert.com.
For further press information please contact Fiona Robinson, The Scott Partnership, 1 Whiteside,
Station Road, Holmes Chapel, Cheshire CW4 8AA, United Kingdom. Phone +44 1477 539539, Fax +44 1477
539540, Email ert@scottpr.co.uk.
About ERT
Based in Philadelphia, PA, eResearchTechnology, Inc. (www.ert.com) is a global provider of
technology and services to the pharmaceutical, biotechnology and medical device industries. The
Company is a market leader in providing centralized core-diagnostic electrocardiographic (ECG)
technology and services to evaluate cardiac safety in clinical development. It is also a leading
provider of centralized respiratory technology and services to evaluate pulmonary function efficacy
and safety in clinical development. Sponsors can further use the Companys solutions to streamline
the clinical trials process by automating the collection, analysis, and distribution of ePRO
clinical data using multi-mode technology in all phases of clinical development as well as selected
medical devices for the clinical trials and healthcare industries.
Statements included in this release may constitute forward-looking statements within the meaning of
the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and
uncertainties, which could cause actual results to differ materially from those expressed or
implied from such statements. These risks and uncertainties include, without limitation, the
Companys ability to obtain new contracts, variability in size, scope and duration of projects,
integration of acquisitions, competitive factors, technological development, market demand, and
other factors described in the Companys filings with the Securities and Exchange Commission. The
Company undertakes no obligation to publicly update any forward-looking statement, whether as a
result of new information, future events, or otherwise.